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Abstract
About 8% of the adult population is taking angiotensin-converting enzyme (ACE) inhibitors to treat cardiovascular disease
including hypertension, myocardial infarction and heart failure. These drugs decrease mortality by up to one-fifth in these
patients. We and others have reported previously that endogenous inhibitory substances suppress serum ACE activity, in
vivo, similarly to the ACE inhibitor drugs. Here we have made an effort to identify this endogenous ACE inhibitor substance.
ACE was crosslinked with interacting proteins in human sera. The crosslinked products were immunoprecipitated and
subjected to Western blot. One of the crosslinked products was recognized by both anti-ACE and anti-HSA (human serum
albumin) antibodies. Direct ACE-HSA interaction was confirmed by binding assays using purified ACE and HSA. HSA
inhibited human purified (circulating) and human recombinant ACE with potencies (IC50) of 5.760.7 and 9.561.1 mg/mL,
respectively. Effects of HSA on the tissue bound native ACE were tested on human saphenous vein samples. Angiotensin I
evoked vasoconstriction was inhibited by HSA in this vascular tissue (maximal force with HSA: 6.1461.34 mN, without HSA:
13.5462.63 mN), while HSA was without effects on angiotensin II mediated constrictions (maximal force with HSA:
18.7362.17 mN, without HSA: 19.2263.50 mN). The main finding of this study is that HSA was identified as a potent
physiological inhibitor of the ACE. The enzymatic activity of ACE appears to be almost completely suppressed by HSA when
it is present in its physiological concentration. These data suggest that angiotensin I conversion is limited by low
physiological ACE activities, in vivo.
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Introduction
The renin-angiotensin-aldosterone system (RAAS) is an impor-
tant regulator of blood pressure and salt-water homeostasis [1].
One of the elements of this system is the angiontensin converting
enzyme. It is a zinc-metalloendodipeptidase which catalyzes the
cleavage of angiotensin I to angiotensin II, and the metabolism of
other peptides such as bradykinin [2]. ACE has two isoenzymes: a
somatic and a testicular form [3]. The somatic form of ACE is
found on the membrane surface of various cells and it can be
released into the circulation by ACE secretase [4,5].
Inhibition of ACE is beneficial in cardiovascular diseases [6–8].
The latest therapeutic guidelines have incorporated all these
therapeutic benefits of ACE inhibition [9–14]. ACE inhibitors are
an important components of a hypothetical polypill proposed to
reduce cardiovascular disease by 80% [15]. Importance of ACE
inhibition may also be highlighted by the fact that there are almost
47,000 hits in the Medline for ‘‘ACE inhibitor’’. The vast majority
of these articles are presenting various features of exogenous ACE
inhibition in animal models and clinical trials.
Interestingly, ACE activity may also be inhibited by endogenous
inhibiting factors, although these endogenous antagonists were
generally neglected in the past decades, in spite of the clinical
success of pharmacological ACE inhibitors. The first reports
regarding these endogenous antagonists dates back to 1979, when
Ryan et al. reported that small (,10 kDa) molecular weight
molecules can inhibit ACE [16]. Several more inhibitors has been
suggested afterward [17–20]. Some efforts were also made to
isolate inhibitory molecules associating with ACE in the rat lung
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[21] or in human sera [22]. In particular, Lieberman reported an
endogenous ACE inhibitor with an apparent molecular mass of .
50 kDa in 1986 (and gained 16 citations so far) [20], Ikemoto and
co-workers reported an endogenous inhibitor (.10 kDa) in 1989
(22 citations) [19].
In a recent work we have confirmed the existence of an
endogenous ACE inhibitor in human sera [23]. Our measure-
ments suggested that it is a serum protein with an apparent
molecular weight of 50–100 kDa [23]. Here we have made an
effort to identify this ACE inhibitory endogenous substance.
Methods
Ethical approval
All of the studies were approved by the Regional and
Institutional Ethics Committee, Medical and Health Science
Center, University of Debrecen, (UDMHSC REC/IEC number:
2894–2008) and by the Medical Research Council of Hungary. All
of the individuals involved gave their written informed consent.
Blood sample collection, serum isolation
Blood samples were collected from volunteers by using a
standard aseptic technique. Native blood was incubated for 60
minutes at room temperature, serum fractions (separated by
centrifugation at 1,500 g for 15 min) were stored at 220uC until
further experiments.
ACE activity measurement using spectrophotometric
assay
The basis of the ACE activity measurement was originally
described by Beneteau et al. [24] and modified by us [23]. The
artificial substrate (FAPGG, (N-[3-(2-furyl)acryloyl]-L-phenylala-
nylglycylglycine; Sigma-Aldrich) was selectively cleaved by serum
ACE in a reaction mixture containing 25 mM HEPES buffer (N-
2-hydroxyethylpiperazine-N-2-ethanesulfonic acid), 0.5 mM
FAPGG, 300 mM NaCl, at pH 8.2. The activity measurements
were performed in 96-well plates (Greiner-Bio One) at 37uC, and
the changes in optical density (340 nm) were measured at 5-min
interval for at least 90 min with a plate reader (NovoStar plate
reader, BMG Labtech). Blank corrected optical density values
were plotted as a function of reaction time and fitted by linear
regression (GraphPad Prism 5.0). The measurement and the
goodness of fitting were accepted, when r2 was .0.90. ACE
activity was calculated by the equation:
activity =2(S/k)*D,
where S is the rate of observed decrease in optical density (1/min),
k is the change in optical density upon the complete cleavage of
1 mmol of FAPGG, and D is the dilution of the serum. ACE
activity is given in units where 1 U is equivalent to the cleavage of
1 mmol of FAPGG in 1 min.
Properties of human serum albumin (HSA)
In some experiments, the ACE activity was measured in the
presence of human serum albumin (HSA, Human BioPlazma
Manufacturing and Trading). The purity of the HSA preparation
was tested by SDS-PAGE (Fig. 1A) and mass spectrometry
(Fig. 1B). Both assays showed a highly purified HSA. HSA was also
tested for absorbed small molecular weight ACE inhibitors. In
these experiments 20 mg/mL HSA was prepared in the buffer
used to measure ACE activity with FAPGG substrate. HSA was
diluted to 10-fold in each step, and filtered with a membrane with
a pore size of 5 kDa. The samples were filtered until the HSA
concentration reached the initial 20 mg/mL. The number of
filtration cycles were 5, 10 and 15. At the end of the filtration
cycles the efficacy of 10 mg/mL HSA was tested on recombinant
ACE inhibition using FAPGG substrate. In addition, captopril
(1 mM) was also used in a parallel measurement to estimate
maximal ACE inhibition.
Measurement of domain specific ACE activity
Domain specific ACE activity was measured as originally
described by Carmona et al. [25] and modified by us [23]. In brief,
quenched fluorescent peptide substrates were used, Abz-
SDK(Dnp)P-OH (Sigma-Aldrich) is highly specific for N domain
active site, Abz-LFK(Dnp)-OH (Sigma-Aldrich) for C domain
active site and Abz-FRK(Dnp)P-OH (Sigma-Aldrich) can be
cleaved by both active sites. The reaction mixtures contained
100 mM tris(hydroxymethyl)aminomethane hydrochloride (TRIS
HCl, Sigma-Aldrich), 50 mM NaCl, 10 mM ZnCl2 and 40 mM
Abz-SDK(Dnp)P-OH or 50 mM Abz-LFK(Dnp)-OH or 10 mM
Abz-FRK(Dnp)P-OH fluorescent substrate, and desired amount of
samples, at pH 7.0. Measurements were performed in black, 96-
well plates (Greiner-Bio One) at 37uC, lex was 340 nm, lem was
405 nm. Changes in fluorescence intensities were measured at 4-
min intervals in case of domain specific substrates for at least
90 min, and at 1.5-min intervals in case of Abz-FRK(Dnp)P-OH
substrate for at least 30 min with a plate reader (NovoStar plate
reader; BMG Labtech). Fluorescence intensity values were plotted
as a function of reaction time and fitted by a linear regression
(GraphPad Prism 5.0). The fit and the data were accepted when r2
was .0.95. ACE activity was calculated via the equation:
activity = (S/k)*D,
where S is the rate of observed increase in fluorescent intensity (1/
min), k is the change in fluorescence intensity upon the complete
cleavage of 1 mmol of fluorescent substrate, and D is the dilution of
the sample. ACE activity is given in units where 1 U is equivalent
to the cleavage of 1 mmol of fluorescent substrate in 1 min.
Partial purification of human serum ACE
Serum samples from a healthy volunteer were ultrafiltered
through ultrafiltration devices with a pore size of 100 kDa
(Vivaspin 500, Sartorius Stedim Biotech) at 4uC for 6 min at
15,000 g. One volume of initial serum samples were diluted to 250-
fold in 25 mM HEPES, pH 8.2 (yielding 250 volume of diluted
serum samples). Then these diluted serum samples were ultra-
filtered until the retained volumes reached the initial volumes of
the serum samples (1 volume).
Expression and purification of recombinant ACE
Recombinant ACE was produced with a Bac-to-Bac TOPO
expression system (Invitrogen) according to the manufacturer’s
instructions. Briefly, a chemically competent E. coli strain
(Invitrogen) was transformed with an ACE gene containing cDNA
plasmid (GeneCopoeia). After antibiotic selection and plasmid
isolation, the pFastBac construct containing the ACE coding
sequence was transformed into DH10Bac competent E. coli
(Invitrogen) to generate recombinant bacmid. The bacmid DNA
was transfected into the SF9 insect cell line (Invitrogen), in which
baculovirus was generated. Further SF9 insect cells were infected
with these bacoluviruses. On day 4, the insect cells were
centrifuged (1,000 g, 10 min, 4uC) and the pellets were washed
in PBS to remove the cell culture medium. The pellet was then
homogenized in radioimmunoprecipitation assay buffer (50 mM
Tris, 150 mM NaCl, 1% Triton X 100, 0.1% SDS, 1%
deoxycholate; RIPA buffer) by sonication (Bandelin Electronic).
The supernatant was collected by centrifugation (15,000 g, 10 min,
4uC), and injected onto an anion-exchange column (Knauer,
Biofox Q) in 25 mM HEPES, 15 mM NaCl, pH 8.2. The ACE
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was eluted with a gradually increasing concentration of NaCl
(from 168 mM to 540 mM, hatched, Fig. 2A). ACE activity was
measured in each collected fractions (300 mL each), and fractions
with at least 50 U/L activity (determined by FAPGG hydrolysis,
hatched, Fig. 2B) were combined. Pharmacological properties of
the recombinant ACE were compared to human serum ACE. No
differences were noted in ACE inhibition by captopril (activity was
determined by FAPGG hydrolysis) when endogenous and
recombinant ACE were used (Fig. 2C).
Detection of the molecular interactions of human ACE
Crosslinking ACE in the serum. Molecular interactions
were stabilized by heterobifunctional crosslinkers. First, the
interactions of ACE in human serum were tested. Sera were
diluted in 6.25 mM HEPES buffer (pH 7.2) and succinimidyl-[(N-
maleimidopropionamido)-dodecaethyleneglycol] ester
(SM(PEG)12), and succinimidyl-[(N-maleimidopropionamido)-hex-
aethyleneglycol] ester (SM(PEG)6), (both from Thermo Scientific)
were then added at concentrations of 1.25 mM, 2.5 mM and
5 mM (labeled +, ++ and +++, respectively in Fig. 3A). The
mixture was incubated for 60 min at room temperature in order to
stabilize intermolecular interactions, and the functional succini-
midyl groups of the crosslinker molecules were then blocked by
50 mM Tris (tris(hydroxymethyl)aminomethane; Sigma-Aldrich)
for 30 min at room temperature. The ACE and the crosslinked
proteins were then immunoprecipitated. Biotinylated goat anti-
human ACE antibody (R&D Systems; 22.6 ng/mL) or goat IgG
(22.6 ng/mL; control) and immobilized streptavidin resin (Pierce)
were added to the mixture to anchor the crosslinked products to
the surface of the resin. The mixture was incubated overnight at
room temperature with continuous agitation, after which the resin-
bound complexes were washed 5 times with 25 mM HEPES
pH 7.2. The immunoprecipitated complexes were then prepared
for SDS-PAGE (the resin was boiled for 10 min in 26
concentrated SDS sample buffer (Sigma-Aldrich)). The samples
were loaded on a 5–15% gradient gel (Mini-Protean TGX Precast
Gel, Bio-Rad Laboratories) and ACE was detected with a goat
anti-human ACE antibody at a dilution of 1:1,000 (R&D Systems),
while the secondary antibody was a peroxidase-linked anti-goat
antibody at a dilution of 1:40,000. The blot was developed on
green sensitive medical X-ray film (Primax Berlin), using the
Western Lightning Plus-ECL reagent (Perkin Elmer Life Sciences).
Testing the interaction of serum ACE with purified
HAS. The molecular interaction between human serum ACE
and HSA was also tested. First, human serum was filtered through
a membrane with a cutoff size of 100 kDa (Vivaspin 500; Sartorius
Stedim Biotech) to remove endogenous HSA and other low
molecular mass proteins but to retain ACE (molecular mass
180 kDa). HSA was obtained from Human BioPlazma, Go¨do¨llo˝,
Hungary. The interaction between ACE and HSA was then tested
by crosslinking (5 mM SM(PEG)6) in the filtered serum. Reaction
mixtures were prepared in the absence or in the presence of 24
and 48 mg/mL HSA (labeled + and ++ in Fig. 3B and 3C,
respectively) under the conditions mentioned above. The mem-
branes were probed with the anti-ACE antibody as mentioned
above, then stripped (incubation in 1% sodiumdodecylsulfate
(SDS, Serva), 20 mM DL-dithiotreitol (DTT, Sigma-Aldrich) and
62.5 mM Tris, pH 7.5 for 20 minutes at 60uC) and re-probed with
a biotinylated anti-HSA antibody (Exbio, Praha) as primary
antibody in a dilution of 1:5,000 (60-min incubation) and
peroxidase-streptavidin in a dilution of 1:100,000 (Jackson; 60-
min incubation) to visualize the position of HSA.
Crosslinking of recombinant ACE and purified
HSA. The interaction between ACE and HSA was tested on
ELISA plates (Greiner Bio-One). First, HSA (Human BioPlazma,
Go¨do¨llo˝, Hungary, 1% in PBS, 300 mL/well) was added to the
Figure 1. Characteristics of Human serum albumin (HSA). Human serum albumin was obtained from Human BioPlazma, Go¨do¨llo˝, Hungary.
The purity of the HSA was tested by SDS-PAGE first (A). There was 6 and 12 mg HSA loaded into the wells. Gel was then stained by Coomassie to
visualize proteins. Apparent molecular masses of a set of standard proteins (arrows on the left) and the expected position of the HSA (arrow on the
right) are indicated. Mass spectrometric (MALDI-TOF) analysis was also done (B). A representative spectrogram is shown on the figure, where the
peaks representing the differently ionized HSA molecules are shown.
doi:10.1371/journal.pone.0087844.g001
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Figure 2. Characteristics of recombinant ACE. Recombinant ACE was produced with a Bac-to-Bac TOPO expression system (Invitrogen)
according to the manufacturer’s instructions. The pellet of baculovirus infected SF9 insect cells was homogenized in radioimmunoprecipitation assay
buffer (RIPA) by sonication. The supernatant was injected onto an anion-exchange column. Column was then washed with a running buffer with
different NaCl contents (shown on A). The ACE was eluted with a gradually increasing concentration of NaCl from 168 mM to 540 mM (hatched, A).
Protein concentration was continuously measured (absorbance at 230 nm, green line, B) while ACE activity was measured in the collected fractions
(300 mL each, red line on Panel B). Fractions with at least 50 U/L activity were combined (determined by FAPGG hydrolysis, hatched, B). Inhibitory
Albumin as an Endogenous ACE Inhibitor
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wells and incubated overnight at room temperature. The next day,
wells were washed 5 times with PBS, SM(PEG)6 and SM(PEG)12
were added (each 625 mM in PBS, 100 mL/well) and the mixtures
were incubated with the surface-bound HSA for 30 min. After
thorough washing (at least 5 times with PBS), 100 mL of 260 ng/
mL recombinant ACE (R&D Systems) was added to the wells for
1 h, the wells were washed at least 5 times with PBS and the
immobilized HSA-linked ACE was detected (Fig. 3D).
Direct measurement of ACE-catalyzed bradykinin
cleavage
Recombinant ACE was incubated with 1 mM bradykinin
(Sigma-Aldrich), 10 mM Amastatin (Sigma-Aldrich), 1 mM Z-
prolyl-prolinal (Enzo Life Sciences) and 300 mM NaCl in 25 mM
HEPES buffer, pH 7.40 in the absence (vehicle) or presence of
40 mg/mL HSA (Human BioPlazma, Go¨do¨llo˝, Hungary) at 37uC.
5 mM EDTA was added to stop the reaction. Bradykinin peptides
were measured after filtering through a filter with a 10 kDa pore
size (Vivaspin, Sartorius Stedim Biotech). Analysis was performed
with a HPLC technique on a reverse-phase C18 column (Hypersil
Gold, Thermo Scientific). Eluent A was 0.01% aqueous trifluor-
oacetic acid (TFA, Sigma-Aldrich), while eluent B was 0.01% TFA
in acetonitrile (Sigma-Aldrich). Bradykinin peptides were separat-
ed by using an elution profile with a gradient from 18%
acetonitrile to 44.2% acetonitrile. They were detected by a diode
array detector at 230 nm and the area under the curve of each
bradykinin peptide peek was compared with calibration curves
recorded when the purified peptide was tested. The amounts of
bradykinin peptides were plotted against the reaction time and
fitted by linear regression. The kinetics of bradykinin cleavage was
normalized to the background (recombinant ACE plus 1 mM
captopril (Sigma-Aldrich)), and compared to vehicle (recombinant
ACE without HSA).
Isometric contractile force measurement on human
saphenous vein segments
Saphenous veins (remained from coronary artery bypass graft
surgery) were cut into circular segments. The veins were placed in
ice-cold physiological buffer solution (containing 110 mM NaCl,
5 mM KCl, 1 mM MgSO4, 1 mM KH2PO4, 5 mM D-glucose,
24 mM NaHCO3, pH = 7.4). Rings were then mounted on a dual
wire myograph system (DMT 510A; Danish Myotechnology). The
organ chamber was filled with oxygenated (10% O2, 5% CO2,
85% N2) physiological buffer solution containing 2.5 mM CaCl2,
and vein segments were stretched at 15 mN and incubated under
isometric conditions for 60 min at 37uC. The viability of the
mounted vascular rings was tested with 56 mM KCl and 10 mM
norepinephrine. The mounted veins were then washed. The
vascular contractile function was tested with 1 mM angiotensin I
and II in the presence or absence of 20 mg/mL HSA. At the end
effect of captopril was tested on the purified recombinant and on the serum ACE. Symbols represent the mean, bars are SEM of the three
independent determinations.
doi:10.1371/journal.pone.0087844.g002
Figure 3. Human serum albumin interacts with the ACE. Human serum samples were incubated with amino (-NH2) and carboxyl (-COOH)
group-reactive heterobifunctional crosslinkers (succinimidyl[(n-maleimidopropionamido)-dodecaethyleneglycol] ester, SM(PEG)12, and succinimi-
dyl[(n-maleimidopropionamido)-hexaethyleneglycol] ester, SM(PEG)6), at concentrations of 1.25, 2.5 and 5 mM (labeled +, ++ and +++, respectively)
for 60 min at room temperature. Free amino groups were then blocked by TRIS (50 mM) and the adducts were immunoprecipitated and detected by
an anti-ACE antibody (A). In some cases the anti-ACE antibody was omitted (first lane, A). The apparent molecular masses of ACE, the IgG heavy chain
and the crosslinked product are shown on the left (A). Similar experiments were performed with purified ACE (100 kDa ultrafiltered serum) and
purified HSA (24 and 48 mg/mL, labeled + and ++, respectively). Crosslinked proteins were precipitated by anti-ACE antibody (except for the first
lanes, where control goat IgG was added) and detected by anti-ACE (B) and anti-HSA (C) antibodies. The positions of the IgG heavy chain, ACE and
the crosslinked product are shown on the left (B), while the positions of the monomeric and multimeric HSA are shown on the right (C). Finally, the
ACE-HSA interaction was also characterized by ELISA assay (D). 96-well plates were coated with HSA (1% in PBS) or with gelatine (1% in PBS)
overnight. Bound proteins were incubated with SM(PEG)12 and SM(PEG)6 (each 625 mM) and recombinant ACE was then added to the wells (26 ng/
well). Bars denote means 6 SEM of the results of 4 independent experiments performed in triplicate.
doi:10.1371/journal.pone.0087844.g003
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of the measurement, the norepinephrine and KCl treatments were
repeated in the presence of the angiotensin peptides to confirm the
viability of the vascular rings. HSA was also applied together with
captopril in some cases.
Statistical analysis
Statistical analysis was performed with Graphpad Prism 5.0
(GraphPad Software) by paired and unpaired t-tests. Differences
were considered to be significant when p,0.05.
Results
The interaction of ACE with its suspected endogenous inhibitor
was stabilized by crosslinking amino and carboxyl groups within
the interacting proteins (crosslinker spacer arm: 5.3 nm). ACE-
containing complexes were then identified by immunoprecipita-
tion and then by using an ACE-specific antibody in Western
blotting (Fig. 3A). Besides the 180 kDa band indicative of free
ACE, an extra band appeared in the crosslinked samples, with an
apparent molecular mass of about 250 kDa (Fig. 3A). The size of
the crosslinked product (about 250 kDa) suggested that the
interaction partner is about 70 kDa. The most abundant plausible
protein with that molecular mass is the human serum albumin
(HSA, 66 kDa). This hypothesized interaction (between ACE and
HSA) was directly tested with purified ACE and HSA by the same
crosslinking technique (Fig. 3B and 3C). The 250 kDa adduct was
again observed and positively stained by both anti-ACE (Fig. 3B)
and anti-HSA antibodies (Fig. 3C) in Western blot. The
interaction between HSA and ACE was further confirmed by
ELISA. HSA, gelatin or ACE specific antibody was immobilized
on the surface of ELISA plates and the binding of ACE to these
surfaces was tested after crosslinking or alternatively when the
crosslinking was blocked or the crosslinkers were omitted (controls
of specificity). Immobilized ACE (crosslinked or antibody bound)
was detected. A high level of crosslinked ACE was detected after
successful crosslinking reactions (first bar, Fig. 3D), but not when
the crosslinking was blocked (second bar, Fig. 3D) or the
crosslinkers were omitted (third bar, Fig. 3D). In contrast with
HSA, ACE crosslinking was not observed in gelatin coated plates
(fourth and fifth bars, Fig. 3D). Finally, the maximum ACE
binding capacity of the surface was estimated by the immobiliza-
tion of an anti-ACE antibody (last bar, Fig. 3D).
Potential inhibitory effect of HSA was also tested on partially
purified ACE from the human sera. Separation of the ACE from
the HSA in human sera (by filtration through a filter device with a
100 kDa pore size) resulted in an increase in ACE activity
(activities at the lowest dilution in Fig. 4A). HSA also inhibited
recombinant human ACE (Fig. 4B) and partially purified serum
ACE (Fig. 4C) activities directly, with half maximal inhibitory
concentrations (IC50) of 9.561.1 and 5.760.7 mg/mL, respec-
tively.
A common clinical side effect of ACE inhibitory therapy is
coughing as a result of elevated bradykinin levels. Effects of
40 mg/mL HSA (saturating concentration in FAPGG hydrolysis,
Fig. 4B) were tested on bradykinin hydrolysis by recombinant
ACE. HSA only partially inhibited bradykinin breakdown
(inhibition by 70.4611.4%, n = 3, p,0.01 compared to vehicle).
ACE has two catalytically active sites, which have slightly
different substrate specificities. Effects of HSA were tested on these
sites by specific fluorescent substrates. It was found that HSA has a
higher affinity for the C-terminal active site (Figure 5).
An effort was made to test whether HSA or some HSA
absorbed dissociative molecules are responsible for ACE inhibi-
tion. Inhibitory effect of a half-maximal concentration of HSA
(10 mg/mL) was tested before (initial sample) and after filtering via
filters with a pore size of 5 kDa (5, 10, 15 filtration cycles) on
recombinant ACE activity. No effect of serial filtration was seen,
while captopril successfully inhibited the ACE activity (Fig. 6).
ACE inhibition by HSA was tested on tissue-bound endogenous
ACE in human vascular preparations (saphenous vein; represen-
tative experiment, Fig. 7A and statistics, Fig. 7B). Angiotensin I or
angiotensin II was applied in the absence (Control) or in the
presence of 20 mg/mL HSA. The combined effects of 20 mg/mL
HSA and captopril (10 mM) was also tested on angiotensin I
responses. There were no significant differences in constrictions to
angiotensin I and II in the absence of HSA (13.562.6 mN, n = 7,
and 19.263.5 mN, n = 7 respectively, Fig. 7B). Angiotensin I
mediated contractions decreased to 6.161.3 mN (n = 6, p = 0.037)
in the presence of HSA while angiotensin II evoked contractions
were not affected (18.762.2 mN, n = 7, Fig. 7B). Addition of
captopril to 20 mg/mL HSA did not affect vascular constriction to
angiotensin I compared to HSA alone (5.561.1 mN, n = 8,
Fig. 7B).
Angiotensin peptide evoked constrictions (unlike norepineph-
rine evoked ones) were transient. Contractile responses diminished
within 10–15 min in the continuous presence of angiotensin
peptides (Fig. 7A) and application of angiotensin II (1 mM) was
without effects in that phase of response (complete desensitization,
Fig. 7A), while norepinephrine was able to evoke constrictions
(Fig. 7A). The maximal contractile capacity of the blood vessel
segments was 22.163.0 mN (Fig. 7B) as determined by norepi-
nephrine.
These transient angiotensin responses were investigated in detail
(Fig. 8). All of the individual traces of contractile responses were
combined to have averaged contractile responses for angiotensin I
(Fig. 8B) and angiotensin II (Fig. 8C) in the absence (blue) or
presence of 20 mg/mL HSA (red). There were no apparent
differences in the angiotensin II responses, while responses to
angiotensin I appeared to be affected by the presence of HSA.
Motivated by these differences several parameters of the contrac-
tile response were determined in each and every individual trace,
including the kinetics of the constriction, duration of the half
maximal contraction, kinetics of desensitization and the level of
desensitization (Fig. 8A), besides to the maximal constriction
described before (Fig. 7B).
The kinetics of constriction was about 3-fold slower in the
presence of HSA than in its absence (40610 mN/s, n = 6;
123630 mN/s, n = 7; p = 0.017; Fig. 9A). In contrast, the presence
of HSA had no significant effect on the kinetics of desensitization
(Fig. 9B), the duration of the half-maximal contraction (Fig. 9C) or
the level of steady-state desensitization (Fig. 9D) in response to
angiotensin I treatment. HSA displayed no significant effect on the
angiotensin II-evoked responses (Fig. 9A–D).
Discussion
The existence of endogenous ACE inhibitors were hypothesized
before our work and being proven in our accompanying paper
[23]. In particular, it was reported earlier that small (,10 kDa)
molecular weight molecules can inhibit ACE in 1979 [16]. Several
more inhibitors has been suggested afterward [17–20]. Some
efforts were also made to isolate inhibitory molecules associating
with ACE in the rat lung [21] or in human sera [22]. There is also
information about an indirect inhibition of ACE by a tissue factor
[26].
Interestingly, we did not find evidence of small molecular weight
ACE inhibitors in human sera [23], although they have been
described previously [16–18]. We did not detect any effect of ,
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50 kDa serum filtrates on ACE activity [23]. One of the most
probable reasons for interpersonal variances can be the diet of the
individuals. It has been reported that dietary factors, such as
bovine alphaS2-casein [27] or components of the honey [28] can
have ACE inhibitory activities. These data suggests that diet rich
in milk products or honey may result in the appearance of small
molecular weight inhibitors. This is an important issue (regulation
of ACE activity by dietary factors) which needs to be tested in
future studies. An alternative explanation is that the observed
small molecular weight inhibitors described in previous studies are
the products of the degradation of large molecular weight ACE
inhibitors, such as HSA [29,30] and that this degradation did not
occur in our samples. Alternatively, the small molecular weight
inhibitors were further metabolized and therefore inactivated in
our case.
It is an important question whether HSA or some HSA
absorbed molecules are responsible for ACE inhibition. The effect
of purified HSA on ACE activity suggested that this inhibitory
effect is rather linked to the HSA than to any other absorbed
molecules. This was further supported by two data of this present
Figure 4. HSA inhibits serum and recombinant ACE. Purification of ACE by filtration through 100 kDa pore size filter devices resulted in
increase in ACE activity from 25.860.3 to 58.661.3 U/L (A). Effects of HSA were tested on recombinant (B) and partially purified ACE (100 kDa
ultrafiltered serum; C). The ACE activity was measured by FAPGG hydrolysis. Symbols denote means 6 SEM of the 3 independent experiments. Data
were fitted by nonlinear regression and the calculated IC50 values are shown. The physiological HSA concentration range (35–52 mg/mL) in human
serum is also indicated by green.
doi:10.1371/journal.pone.0087844.g004
Figure 5. HSA has higher affinity for the C-terminal active site
of purified ACE. Inhibition of serum ACE was tested by active site
specific fluorescent substrates: Abz-SDK(Dnp)P-OH (blue bars) for the N-
terminal active site, Abz-LFK(Dnp)-OH (red bars) for the C-terminal
active site. Abz-FRK(Dnp)P-OH (black bars) was used as non-site specific
substrate. Bars represent means 6 SEM of 3 independent determina-
tions, values are given in the percentage of control (vehicle, without
ACE inhibitor).
doi:10.1371/journal.pone.0087844.g005
Figure 6. There is no dissociative small molecular weight ACE
inhibitor absorbed by the HSA. HSA was diluted to 20 mg/mL in
FAPGG reaction buffer and split into 4 fractions with identical volume.
The first was used as a control (initial sample, 0 filtration cycles). The
HSA was diluted in the other fractions by 10-fold and filtered through
5 kDa pore size membranes until the HSA concentration (and volume)
of the retained fractions reached the original 20 mg/mL. This filtration
step was repeated by 5, 10 or 15 times as indicated on the figure. The
effects of these HSA fractions were tested on recombinant ACE using
FAPGG substrate at a final concentration of 10 mg/mL. Maximal ACE
activity was determined in the absence of HSA (vehicle). Captopril
(1 mM) was also used to estimate the effect of complete ACE inhibition
on FAPGG hydrolysis.
doi:10.1371/journal.pone.0087844.g006
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manuscript. First, the applied HSA was found to be remarkably
pure by mass spectrometry. Second, HSA ability to inhibit
recombinant ACE was not affected by up to 15 filtration cycles,
suggesting that HSA inhibition is not the result of some dissociative
absorbed molecules.
Interestingly, some studies designed to identify dietary compo-
nents with ACE inhibitory activity lead to the recognition of
Acein-1 [29] and albutensin A [30] as tryptic fragments of serum
albumin with ACE inhibitory properties. These peptides were
synthesized and inhibited ACE, pinpointing HSA regions poten-
tially important in ACE inhibition. Acein-1 was identified as a
heptapeptide (Tyr-Leu-Tyr-Glu-Ile-Ala-Arg) spanning the region
138–144 in HSA, while albutensin A is a nonapeptide (Ala-Phe-
Lys-Ala-Trp-Ala-Val-Ala-Arg) [30] spanning the region 210–218
in HSA. The existence of these peptides suggest that HSA may
have multiple ACE inhibitory sites. Moreover, both peptides have
IC50 values similar to that determined for HSA here (16 mM for
acein-1 [29] and 1.2 mM for albutensin A [30]). Interestingly, the
synthetic peptide, which is a single residue longer than acein-1 had
a dramatically lower IC50 (500 mM versus 16 mM for acein-1)
suggesting that position and exposition of these segments of HSA
on the surface may have a dramatic effect on their effectiveness.
It become also apparent during the completion of our studies
that we are not the first to identify the full length HSA as an
endogenous inhibitor of ACE. Klauser et al. has already identified
HSA as an endogenous inhibitor of ACE in 1979 [31]. Moreover,
they also have identified HSA as a noncompetitive inhibitor, with
a Ki value about 3 mM, shown here or in the accompanying paper
Figure 7. HSA inhibits tissue ACE in human vascular bed. Human saphenous vein rings were mounted on an isometric contractile force
measurement setup. Vessels were treated with angiotensin peptides (angiotensin I in A) at 1 mM for an extended period of time (without washing).
The vascular segments contracted, as indicated by the increase in contractile force, and then relaxed in the continuous presence of angiotensin I. At
the end of the experiment, 1 mM angiotensin II was added to confirm desensitization, and the viability of the vessel was finally tested with
norepinephrine (100 mM). An individual experiment is illustrated in A, force was recorded in every 0.5 s. The effects of HSA were tested on separate
vascular segments. Maximal contractile responses are shown on the bar graph (B) to angiotensin peptides in the absence (Control, blue) or presence
of 20 mg/mL HSA (red), in the presence of 20 mg/mL HSA plus 10 mM captopril (yellow) or norepinephrine (green). Bars denote means 6 SEM,
significant difference is indicated by the p value.
doi:10.1371/journal.pone.0087844.g007
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Figure 8. HSA slows down the kinetics and inhibits angiotensin I evoked constrictions in saphenous vein segments. Several
parameters of transient contractile response to angiotensin peptides were investigated, including maximal force, kinetics of contraction, duration of
half-maximal contraction, kinetics of desensitization and the level of desensitization (A). The responses evoked by angiotensin I (B) and angiotensin II
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[23]. The main novelty of the present study is therefore not the
identification of HSA as an endogenous inhibitor of ACE, this is
only a re-discovery. Nonetheless, we extended our efforts to (1)
investigate the effects of HSA on tissue ACE, which is probably
has not been done before. In addition (2) we discovered that HSA
is probably more sensitive for the C-terminal active site of the
serum ACE, and (3) affects angiotensin I and bradykinin
hydrolytic activity of ACE differently.
One of the questions regarding our work is the physiological
relevance of the findings. Physiological HSA concentrations are
several times higher (35–52 mg/mL) than the determined IC50
values for HSA (5.7 and 9.75 mg/mL), suggesting complete
suppression of ACE activity by HSA, in vivo. Moreover, ACE
inhibition by HSA were tested on human sera and human blood
vessels. Our data suggest that ACE activity is significantly
suppressed as long as the HSA concentration is at least
,30 mg/mL [32]. Nonetheless, the HSA concentration may be
lower in conditions associated with protein malnutrition and liver
failure, among others. Our findings tend to indicate that under
these conditions the infusion of HSA may increase the inhibition of
ACE. In accordance with this, it has been found, that the
postoperative infusion of HSA frequently evokes hypotension in
patients receiving ACE inhibitor therapy [33].
ACE inhibitor drugs are particularly effective in cardiovascular
diseases, pinpointing ACE as a major angiontensin I converting
enzyme, in vivo. HSA was identified here as a major inhibitor of
circulating ACE, suggesting that ACE inhibitor drugs are probably
not acting on the circulating ACE, since it has already been
suppressed by the physiological concentration of the endogenous
HSA. ACE inhibitor drugs should therefore target a tissue-bound
ACE population. HSA inhibited angiotensin I conversion in the
vascular tissue, resulting in a slower and lower maximal
angiotensin I mediated constriction in human vascular bed. This
effect of HSA was independent of angiotensin II evoked
constrictions, suggesting a direct effect on tissue bound ACE,
but the efficacy of HSA at 20 mg/mL appeared to be lower in the
(C) in the absence (blue) and in the presence (red) of 20 mg/mL HSA were recorded on 35 vascular segments from 20 patients. The recorded values
were aligned according to the position of the maximal response and the mean 6 SEM for each time point was calculated and plotted (mean, thick
line, and SEM, thin line; B and C).
doi:10.1371/journal.pone.0087844.g008
Figure 9. HSA affects the rate of angiotensin evoked force development in human vascular bed. Functional parameters such as kinetics
of contraction (A), the kinetics of desensitization (B), the duration of half-maximal contraction (C), and the level of desensitization (D) were
determined upon angiotensin contractions. Experiments were performed in the absence (blue) or presence (red) of 20 mg/mL HSA. Bars denote
means 6 SEM. Significant difference is shown by the p value.
doi:10.1371/journal.pone.0087844.g009
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case of tissue-bound ACE than that is for serum ACE. In addition,
captopril (an ACE inhibitory drug) was not more effective than
HSA in the same assay (even applied at high concentrations),
suggesting that either captopril is not a complete antagonist at
vascular ACE or alternatively, angiotensin I responses were not
exclusively mediated by ACE in this location.
Our data provide evidence that endogenous HSA suppresses
serum ACE. This can be a mechanism to suppress circulating
ACE mediated conversion of angiotensin I, which can lead to
systemic (nonspecific) effects (Fig. 10). On the other hand the high
level of endogenous ACE inhibition by physiological concentra-
tions of HSA suggests that this circulating ACE probably can not
be further inhibited by ACE inhibitory drugs. It appears that an
other (tissue-bound) ACE pool is inhibited by these drugs, on
which HSA mediated inhibition is not as prominent. One of our
novel messages is that ACE activity measurement can mislead in
terms of ACE concentration (for example the presence of HSA in
the samples result in lower activity values), but it also helps to
identify the most likely sources of tissue ACE which is probably not
fully inhibited by HSA, in vivo. Cushman and Cheung identified
the lung as one of the primary source of active ACE [34],
pinpointing this location when one is looking for HSA resistant
ACE.
We hypothesize that HSA does not inhibit all forms of ACE
similarly (Fig. 10). According to this hypothesis ACE in some
tissues has lower affinity for HSA or has higher local concentration
(expression level) than that is in the serum. HSA mediated
inhibition is therefore only limited in these locations, while ACE
inhibitory drugs can potently inhibit these enzymes. Under these
conditions HSA may inhibit somewhat local ACE activity, but it
can be further inhibited by these ACE inhibitor drugs. This is in
accordance with a recent consensus report [35] stating that ‘‘the
plasma ACE represents only a small proportion of the body’s total
ACE activity, therefore its role is thought to be minimal’’. As a
matter of fact we have provided a mechanism for this ‘‘minimal
contribution’’ by showing HSA mediated suppression of plasma
ACE.
An other implication of the high degree of inhibition of serum
ACE by HSA is that ACE mediated angiotensin I to angiotensin II
conversion can be a rate limiting step in the renin-angiotensin-
aldosterone system (RAAS). It is in accordance with the co-
existence of both angiotensin I and angiotensin II in the circulation
in a comparable level [36], suggesting that the rate of angiotensin I
generation (by renin) and conversion (by ACE) are not much
different, albeit angiotensin I can not be present at such
concentrations without the activation of the renin. Nonetheless,
this high degree of ACE inhibition by HSA suggests that the
processes responsible for the elimination of the angiotensin II can
play a significant role in the determination of local angiotensin II
levels. The clinical relevance of this hypothesis was shown in an
accompanying paper [37].
There are at least three perspectives which need to be addressed
by further studies. First, our results additionally point to new
pharmacological strategies for the design of novel ACE inhibitors
which could possibly stabilize the interaction between ACE and
HSA, thereby resulting in ACE inhibition for a prolonged period.
Second, the observed inhibitory effects of HSA on ACE in the sera
suggest the existence of a physiological ACE suppressing system.
HSA may theoretically stabilize ACE activities at a very low level
irrespectively of the actual ACE concentration. In this process, the
HSA is present in excess and the ACE associates and being
inhibited with the excess HSA even if there are slight differences in
ACE concentrations (similarly to hydrogen ions (analogous to
ACE here) and buffers (analogous to HSA here)). This has been
addressed by an accompanying clinical paper [32]. Third,
physiological ACE activities may be very low and angiotensin II
Figure 10. Hypothetical model for the effects of human serum albumin (HSA) on the angiotensin I converting enzyme (ACE)
activity. We found a high degree of serum ACE inhibition by physiological concentrations of HSA. This may provide a mechanism for suppressing
the circulating ACE, confining angiotensin I conversion to the tissues. Vascular tissue-bound ACE was also found to be inhibited by HSA, in vitro.
However, ACE inhibitor drugs are markedly effective in hypertension and heart failure. Since serum ACE is suppressed by HSA, ACE inhibitor drugs
can probably not inhibit more effectively this ACE population. This can only be explained by the hypothesis that HSA does not uniformly inhibit
tissue-bound ACE in the human body. Some of tissue-bound ACE can be inhibited by ACE inhibitor drugs over the inhibition provided by HSA.
doi:10.1371/journal.pone.0087844.g010
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availability may be also controlled by its elimination (metabolism),
besides to its synthesis. This hypothesis can be tested by studying
ACE2 levels in various cardiovascular diseases as was proven in an
accompanying paper [37], such as hypertension and heart failure,
where ACE inhibitors are particularly effective.
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